Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
Kodiak Sciences completed enrollment of the first 300-patient cohort in the Phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation (MESI). The company reaffirmed that topline clinical data from this pivotal cohort remains on track for release in December 2026, with the second pivotal cohort of 600 subjects expected to complete enrollment in the fourth quarter of 2026.
Key figures
- Drug Name
- KSI-101
- Phase Of Trial
- Phase 3
- Subjects cohort 1
- 300
- Subjects cohort 2
- 600
- Topline data date cohort 1
- December 2026
- Topline data date cohort 2
- 2Q 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.